The metabolism od 2:4:5-trihydroxybutyrophenone in the rat and dog.
نویسندگان
چکیده
The widespread use of phenolic antioxidants as stabilizers in foodstuffs raises the question of the manner of their disposal after intake by the animal body. It is intended to investigate the metabolism of several phenolic antioxidants, and in this paper some aspects of the metabolism in the rat and dog of 2:4:5-trihydroxybutyrophenone are discussed. This study was made during chronic-toxicity studies designed to test the suitability of 2:4:5trihydroxybutyrophenone for use as an antioxidant in foodstuffs. The metabolism of the pure compound in rats and dogs, its excretion in urine and faeces, the extent of its storage in tissues at various dose levels, and the period of retention of a single dose as 2:4:5-trihydroxybutyrophenone and any metabolic products have been examined. The metabolism of 2:4:5-trihydroxybutyrophenone presents several potentially interesting features arising from the presence of a polyhydric phenolic nucleus and a butyryl side chain. Although the metabolism of phenols has been extensively studied (Williams, 1949) and the principal routes (ethereal sulphate and glucuronide conjugation, oxidation to polyhydric phenols) are well known, much less information is available about the metabolism of polyhydric phenols. The problem of the orientation of conjugation has been discussed (Dodgson, Smith & Williams, 1950) for phenols having more than one hydroxyl available for conjugation. It seemed of particular interest to see whether 2:4:5-trihydroxybutyrophenone underwent conjugation, whether more than one conjugate was produced and whether conjugates of different orientation were formed.
منابع مشابه
Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) is a novel multitargeted, orally active protein tyrosine kinase inhibitor. The inhibition constants (K(i)) of TG100435 against Src, Lyn, Abl, Yes, Lck, and EphB4 range from 13 to 64 nM. TG100435 has systemic clearance values of 20.1, 12.7, and 14.5 ml/min/kg and oral bioavailabilit...
متن کاملOxidative cleavage of the octyl side chain of 1-(3,4-dichlorobenzyl)-5-octylbiguanide (OPB-2045) in rat and dog liver preparations.
The metabolism of 1-(3,4-dichlorobenzyl)-5-octylbiguanide (OPB-2045), a new potent biguanide antiseptic, was investigated using rat and dog liver preparations to elucidate the mechanism of OPB-2045 metabolite formation, in which the octyl side chain is reduced to four, five, or six carbon atoms. Chemical structures of metabolites were characterized by 1H NMR, fast atom bombardment/mass spectrom...
متن کاملO-10: The Effects of Different Transplantation Sites on Follicular Surviving and Apoptosis Incidenceof Intact Whole Rat Ovaries after Autotransplantation
Background: Limited and fixed number of ovarian follicles undergo reducing changes from birth till menopause. In cancerous patients who exposed to sterilizing treatments such as chemotherapy, follicle decrease is faster and dominant. Main fertility preservation technique for these patients is ovarian cryopreservation and transplantation. Reanastomosis between recipient site and invader tissue i...
متن کاملThe metabolism of arylazoisoxazolones by rats and dogs.
1. When rats were given a single oral dose of the lipid-soluble fungicide 4-(2-chlorophenylhydrazono)-3-methyl[4-(14)C]isoxazol-5-one ([(14)C]drazoxolon), about 75% of the label was excreted in the urine and 13% in the faeces in 96hr. An additional 7% of the radioactivity was recovered as (14)CO(2) in 48hr. 2. About 8% of the label was excreted by rats in the bile in 0-24hr. and an additional 6...
متن کاملImatinib metabolism and disposition in isolated rat perfused liver
Imatinib is an orally administered tyrosine kinase inhibitor which inhibits the Bcr-Abl protein-tyrosine kinase with high selectivity. Imatinib is rapidly absorbed from the gut, after oral intake and has an almost absolute bioavailability of 98%. The metabolism of imatinib is mediated by the cytochrome P450 (CYP) isoenzymes in the liver and gut wall. CGP74588 is a major active metabolite of ima...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Biochemical journal
دوره 72 شماره
صفحات -
تاریخ انتشار 1959